News

The trial is being conducted in collaboration with the Dana-Farber/Partners Cancer Care (DFPCC), a joint venture non-profit consortium established by Massachusetts General Hospital, The Brigham and Women’s Hospital,

The device was developed in collaboration Professor Donna Davies and Dr Judith Holloway from the University’s school of medicine, and Philips Research. The University said that the next

Preliminary results from the trial indicate that inhaled TPI-ASM8 was safe and well tolerated and demonstrated protection in early and late stage allergic responses in patients with asthma.

Zelapar is the first Parkinson’s disease treatment to use a novel oral delivery system called Zydis technology, which allows the tablets to dissolve within seconds in the mouth

Roche will fund the research, which will be conducted by both Roche and Emisphere. Financial terms of the agreement were not disclosed. Emisphere’s eligen technology is used to

The expanded trial was prompted by encouraging interim safety and efficacy data recently reported for single-dose administration of CG0070 and will include up to 45 additional patients who

Researchers at Harvard’s Beth Israel Deaconess Medical Center (BIDMC) will attempt to verify the pharmacokinetic and pharmacological properties of PT-401, DNAPrint’s lead product in development. “We expect that

REP8839 is being developed in combination with mupirocin, a widely used topical antibiotic. The study will examine various concentrations of REP8839 alone and in combination with mupirocin versus

Under the agreement, DAC will access compound intellectual property that Evotec has generated on this disease target through its internal R&D activities. The aim of the collaboration will